Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. [electronic resource]
Producer: 20191216Description: 612-620 p. digitalISSN:- 1532-1827
- Animals
- CHO Cells
- Clinical Trials, Phase II as Topic
- Cricetulus
- Drug Resistance, Neoplasm
- Female
- Gastrointestinal Neoplasms -- drug therapy
- Gastrointestinal Stromal Tumors -- drug therapy
- Humans
- Imatinib Mesylate -- pharmacology
- Mice
- Mice, Nude
- Mutation
- Phenylurea Compounds -- pharmacology
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins c-kit -- antagonists & inhibitors
- Pyridines -- pharmacology
- Sunitinib -- pharmacology
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.